HC Wainwright Has Positive Outlook for NERV FY2024 Earnings

Minerva Neurosciences, Inc. (NASDAQ:NERV) – HC Wainwright boosted their FY2024 EPS estimates for shares of Minerva Neurosciences in a report released on Wednesday, November 6th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings of ($0.30) per share for the year, up from their prior forecast of ($2.26). HC Wainwright has a “Neutral” rating and a $5.00 price objective on the stock. The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($2.26) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q4 2024 earnings at ($1.05) EPS, Q1 2025 earnings at ($1.07) EPS, Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($2.68) EPS, FY2026 earnings at ($1.88) EPS, FY2027 earnings at $0.00 EPS and FY2028 earnings at $1.62 EPS.

Separately, StockNews.com started coverage on Minerva Neurosciences in a research report on Saturday, November 2nd. They set a “sell” rating on the stock.

Minerva Neurosciences Stock Performance

Shares of Minerva Neurosciences stock opened at $2.34 on Friday. The business has a fifty day simple moving average of $2.62 and a 200-day simple moving average of $2.79. Minerva Neurosciences has a fifty-two week low of $2.26 and a fifty-two week high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.12).

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.